Table 4 PFS and OS in relation to haplotypes.

From: Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer

 

Progression-free survival

Overall survival

Median PFS (95%CI)

HR (95% CI)

p

HR* (95% CI)

p*

Median OS (95%CI)

HR (95% CI)

p

H1/H1

13.9 (12.2–19.3)

0.73 (0.50–1.08)

0.12

  

28.4 (18.6–38.6)

0.86 (0.56–1.32)

 

Other

11.6 (10.4–13.1)

1.00

  

21.1 (17.3–29.8)

1.00

0.49

H2/H2

9.59 (6.9-NA)

2.25 (1.26–4.03)

0.006

2.83 (1.33–5.99)

 

15.2 (9.79-NA)

1.63 (0.91–2.90)

 

Other

12.52 (11.6–14)

1.00

1.00

0.006

24.4 (19.75 -30.3)

1.00

0.1

H1/H1 + H2/H2

12.3 (9.76–14.8)

0.95 (0.67–1.34)

0.75

  

22.6 (16.7–37.8)

1.05 (0.72–1.53)

 

Other

12.0 (11.2–13.9)

1.00

  

23.4 (18.9–30.3)

1.00

0.8

  1. H1/H1, Haplo1/Haplo1; H2/H2, Haplo2/Haplo2; H1/H1 + H2/H2, Haplo1/Haplo1 + Haplo2/Haplo2.
  2. *Ajusted HR and p-value.
Back to article page